Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Iitacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)

NCT02018861 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT02018861
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02018861 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Iitacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)
Lead sponsor
Incyte Corporation
Phase
Phase 1/2
Overall status
Completed
Start date
September 22, 2016
Completion date
April 12, 2021
Enrollment
88 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell malignancies